Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.
Loading...
LTHT Department
Contributor Profession (Non Medical)
Publication Date
Item Type
Journal Article
Language
Subject
Subject Headings
Journal Title
Journal ISSN
Volume Title
Abstract
Journal
Haematologica